State Key Laboratory of Advanced Technology for Materials Synthesis and Processing, Biomedical Materials and Engineering Research Canter of Hubei Province, Wuhan University of Technology, Wuhan 430070, China.
School of Chemistry, Chemical Engineering and Life Science, Wuhan University of Technology, Wuhan 430070, China.
J Mater Chem B. 2024 Mar 27;12(13):3282-3291. doi: 10.1039/d4tb00009a.
Sonodynamic therapy (SDT), an emerging cancer treatment with significant potential, offers the advantages of non-invasiveness and deep tissue penetrability. The method involves activating sonosensitizers with ultrasound to generate reactive oxygen species (ROS) capable of eradicating cancer cells, addressing the challenge faced by photodynamic therapy (PDT) where conventional light sources struggle to penetrate deep tissues, impacting treatment efficacy. This study addresses prevalent challenges in numerous nanodiagnostic and therapeutic agents, such as intricate synthesis, poor repeatability, low stability, and high cost, by introducing a streamlined one-step assembly method for nanoparticle preparation. Specifically, the sonosensitizer Chlorin e6 (Ce6) and the chemotherapy drug erlotinib are effortlessly combined and self-assembled under sonication, yielding carrier-free nanoparticles (EC-NPs) for non-small cell lung cancer (NSCLC) treatment. The resulting EC-NPs exhibit optimal drug loading capacity, a simplified preparation process, and robust stability both and , owing to their carrier-free characteristics. Under the synergistic treatment of sonodynamic therapy and chemotherapy, EC-NPs induce an excess of reactive oxygen in tumor tissue, prompting apoptosis of cancer cells and reducing their proliferative capacity. Both and experiments demonstrate superior therapeutic effects of EC-NPs under ultrasound conditions compared to free Ce6. In summary, our research findings highlight that the innovatively designed carrier-free sonosensitizer EC-NPs present a therapeutic option with commendable efficacy and minimal side effects.
声动力学疗法（SDT）是一种具有巨大潜力的新兴癌症治疗方法，具有非侵入性和深组织穿透力的优点。该方法涉及用超声波激活声敏剂以产生能够消灭癌细胞的活性氧（ROS），解决了光动力疗法（PDT）面临的挑战，即传统光源难以穿透深部组织，影响治疗效果。本研究通过引入一种简化的一步组装方法来制备纳米粒子，解决了许多纳米诊断和治疗剂中存在的复杂合成、重复性差、稳定性低和成本高的问题。具体来说，声敏剂氯己定（Ce6）和化疗药物厄洛替尼在超声作用下轻松地结合并自组装，得到无载体纳米粒子（EC-NPs），用于治疗非小细胞肺癌（NSCLC）。由于其无载体的特性，所得的 EC-NPs 表现出最佳的药物负载能力、简化的制备工艺和强大的稳定性。在声动力学疗法和化疗的协同治疗下，EC-NPs 在肿瘤组织中诱导过量的活性氧，促使癌细胞凋亡并降低其增殖能力。实验均表明，与游离的 Ce6 相比，超声条件下 EC-NPs 的治疗效果更好。总之，我们的研究结果表明，这种创新设计的无载体声敏剂 EC-NPs 是一种具有良好疗效和最小副作用的治疗选择。
